The role of intraperitoneal chemotherapy in epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 10, Issue SUPPL. 1, 2000, Pages 26-32

  Vermorken, J B ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; MELPHALAN; METHOTREXATE; MITOMYCIN C; PACLITAXEL;

AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TUMOR VOLUME;

EID: 0034003372     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2000.99507.x     Document Type: Article

References (36)

1. Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Semin Oncol 1998; 25: 326-34.
2. McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Semin Oncol 1998; 25: 340-8.
3. Hoskins PJ, O'Reilly SE, Swenerton KD. Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy. J Clin Oncol 1992; 10: 1561-8.
4. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. BMJ 1991; 303: 884-93.
5. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL et al. Long-term survival in ovarian cancer. Eur J Cancer 1991; 27: 1367-72.
6. Vermorken JB, Harper PG, Buyse M. The role of anthracyclines in epithelial ovarian cancer. Ann Oncol 1999; 10 (Suppl. 1): 43-50.
7. Hoskins P, Eisenhauer E, Fisher B et al. Sequential couplets of cisplatin (DDP) /topotecan (TOP) and cisplatin/ paclitaxel (T) as first-line therapy for advanced epithelial ovarian cancer (EOC): an NCIC Clinical Trials Group phase II study. Proc Am Soc Clin Oncol 1999; 18: 357a (Abstract #1378).
8. Hansen SW, Anderson H, Boman K et al. Gemcitabine, carboplatin, and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV. Proc Am Soc Clin Oncol 1999; 18: 357a (Abstract #1379).
9. Vermorken JB. Consolidation therapy in patients with advanced ovarian cancer. Eur J Gynaecol Oncol 1994; 15: 7-13.
10. Sorbe B, Tropé C, Nordal R et al. Consolidation treatment of ovarian carcinoma, stage III, at complete surgical remission after induction chemotherapy. Int J Gynecol Cancer 1999; 9 (Suppl. 1): 58 (Abstract #A176).
11. Pickel H, Lahousen M, Petru E et al. Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer. Int J Gynecol Cancer 1999; 9 (Suppl. 1): 53 (Abstract #A161).
12. Ozols RF, Gore M, Trope C, Grenman S. Intraperitoneal treatment and dose-intense therapy in ovarian cancer. Ann Oncol 1999; 10 (Suppl.1): 59-64.
13. Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978; 62: 1-11.
14. Markman M. Intraperitoneal chemotherapy. Semin Oncol 1991; 18: 248-54.
15. Markman M. Intraperitoneal therapy of ovarian cancer. Semin Oncol 1998; 25: 356-60.
16. Markman M, Reichman B, Hakes T et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 1991; 9: 1801-5.
17. Los G. Experimental Basis of Intraperitoneal Chemotherapy PhD Thesis, Amsterdam, The Netherlands: Vrije Universiteit 1990.
18. Markman M, Reichman B, Hakes T et al. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-vol. residual ovarian cancer. J Clin Oncol 1992; 10: 1479-84.
19. van Rijswijk REN, Hoekman K, Burger CW, Verheijen RHM, Vermorken JB. Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease. Ann Oncol 1997; 8: 1235-41.
20. Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group study. J Clin Oncol 1998; 16: 2620-4.
21. Markman M, Rowinsky E, Hakes T et al. Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J Clin Oncol 1992; 10: 1485-91.
22. Goel R, Cleary SM, Horton CA et al. Effect of sodium thiosulfate on the pharmacokinetics and toxicity of cisplatin. J Nat Cancer Inst 1989; 81: 1552-60.
23. Elferink F, van der Vijgh WJF, Klein I et al. Pharmacokintics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol 1988; 21: 57-60.
24. ten Bokkel Huinink WW, Aartsen E, Franklin H, McVie JG. Experimental and clinical results with intraperitoneal cisplatin. Semin Oncol 1985; 12 (Suppl. 4): 43-6.
25. Howell SB, Pfeifle CL, Wung WE et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982; 97: 845-51.
26. Howell SB. Intraperitoneal chemotherapy: the use of concurrent systemic neutralizing agents. Semin Oncol 1985; 12 (Suppl. 4): 17-22.
27. Berek JS, Bertelsen K, du Bois A et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999; 10 (Suppl. 1): 87-92.
28. Los G, Verdegaal EME, Mutsaers PHA, McVie JG. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol 1991; 28: 159-65.
29. Markman M, Reichman B, Hakes T et al. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-vol. residual ovarian cancer. Gynecol Oncol 1993; 50: 100-4.
30. Piccart MJ, Speyer JL, Markman M et al. Intraperitoneal chemotherapy: technical experience at five institutions. Semin Oncol 1985; 12 (Suppl. 4): 90-6.
31. Howell SB, Zimm S, Markman M et al. Long-term survival of advanced refractory ovarian carcinoma patients with small-Vol. disease treated with intraperitoneal chemotherapy. J Clin Oncol 1987; 5: 1607-12.
32. Barakat R, Almadrones L, Venkatraman E, Spriggs D. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment. Proc Am Soc Clin Oncol 1997; 16: 354a (Abstract #1264).
33. Kirmani S, Braly PS, McClay EF et al. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol 1994; 54: 338-44.
34. Deleted in proof.
35. Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950-5.
36. Markman M, Bundy B, Benda J et al. Randomized phase 3 study of intravenous (iv) cisplatin/paclitaxel versus moderately high dose iv carboplatin followed by iv paclitaxel and intraperitoneal cisplatin in optimal residual ovarian cancer. Proc Am Soc Clin Oncol 1998; 17: 361a (Abstract #1392).